Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Joseph F HayesLouise MarstonKate WaltersJohn R GeddesMichael KingDavid P J OsbornPublished in: PLoS medicine (2016)
Lithium use is associated with more renal and endocrine adverse events but less weight gain than commonly used alternative mood stabilizers. Risks need to be offset with the effectiveness and anti-suicidal benefits of lithium and the potential metabolic side effects of alternative treatment options.
Keyphrases
- bipolar disorder
- weight gain
- major depressive disorder
- body mass index
- birth weight
- human health
- depressive symptoms
- randomized controlled trial
- solid state
- systematic review
- weight loss
- sleep quality
- risk assessment
- emergency department
- combination therapy
- physical activity
- gestational age
- climate change
- adverse drug
- smoking cessation
- electronic health record